Optimized antibiotic treatment in Korean patients with Clostroides difficile infection

Comparative study for optimized antibiotic treatment in Korean patients with Clostroides difficile infection

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006008

Enrollment

438

Registered

2021-03-16

Start date

2021-06-16

Completion date

Unknown

Last updated

2024-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : We compare metronidazole and vancomycin use groups in mild and moderate C. difficile infections and metronidazole and vancomycin use groups in severe Clostroides difficile infections. For metro

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria Adults aged 19 to 85, patients with clinical symptoms, laboratory tests confirmed CDI. Patients not receiving CDI treatment in the past 10 days Patients of childbearing potential who are not pregnant prior to participation in the clinical trial

Exclusion criteria

Exclusion criteria: Exclusion criteria Patients who have experienced at least one CDI within 3 months prior to participation in the clinical trial Patients taking to be treated with prohibited medications Pregnant or lactating women Patients with ulcerative colitis or Crohn's disease Patients undergone colon resection Patients has a current diagnosis of toxic megacolon Patient has hypersensitivity to metronidazole Patients has hypersensitivity to vancomycin

Design outcomes

Primary

Measure	Time frame
Cure Rate at End of Therapy	—

Secondary

Measure	Time frame
Recurrence;Global Cure	—

Countries

Korea, Republic of

Contacts

Public ContactYoung-Seok Cho

The Catholic University of Korea, Seoul St. Mary's Hospital

joydoctor87@gmail.com+82-2-1588-1511

Outcome results